Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nihon Hansenbyo Gakkai Zasshi ; 80(3): 275-85, 2011 Sep.
Artigo em Japonês | MEDLINE | ID: mdl-21941834

RESUMO

Treatment of erythema nodosum leprosum (ENL, type 2 reaction) using thalidomide provides effective alternative choice to steroid therapy. Yet, the Japanese National Health Insurance approves thalidomide prescription only for the treatment of multiple myeloma under the Thalidomide Education and Risk Management System (TERMS). Benefit of thalidomide therapy for patients with ENL is already an established fact based on various reports from other countries, but limited experiences and standards in Japan have hindered application of the medication to our patients. This led us to compose a local guideline. Based on and following the TERMS, we suggest starting thalidomide from 50-100 mg/day and then onwards adjusting the dose according to the symptoms of each patient, not to exceed the maximum recommended dose of 300 mg/day, for the treatment of ENL.


Assuntos
Eritema Nodoso/tratamento farmacológico , Hansenostáticos/administração & dosagem , Hanseníase Virchowiana/tratamento farmacológico , Guias de Prática Clínica como Assunto , Talidomida/administração & dosagem , Humanos , Japão , Hansenostáticos/efeitos adversos , Gestão de Riscos , Talidomida/efeitos adversos
2.
Nihon Hansenbyo Gakkai Zasshi ; 78(3): 293-6, 2009 Sep.
Artigo em Japonês | MEDLINE | ID: mdl-19803381

RESUMO

The number of ex-leprosy patients has reduced rapidly who were forced to be admitted under leprosy prevention/segregation law and are staying at national sanatoriums with different disabilities due to different physical and social reasons for long time in Japan. Most of them have been of clinically cured status for decades after effective chemotherapy. Some have still been suffering from acute or chronic neuralgic pains which are supposed to be long standing consequences of nerve damage of leprosy and getting medications for long period. Pharmacy department of National Suruga Sanatorium has studied the amount of prescriptions of some medicines for last 11 years, which were thought to be prescribed for pain including neuralgic pain. There seem to be some tendencies of medications during last decade. VitaminB12 (Mecobalamine) is one of the commonest drugs for neuralgic pain at this sanatorium and the amount of prescription had almost been unchanged through the years. Prescription of non-steroid anti-inflammatory drugs (NSAIDs) increased year by year, which may reflect the increasing age of ex-patients who need more pain killers for their painful joints or back. Loxoprofen is the most popular pain killer here and increased by ten times for last decade. The number of prescription for Pentazocine and Hydroxyzine Hydrochloride injection increased for last several years, which reflects a few patients who were still suffering from severe chronic neuralgia for years. It is desirable that a standard regimen for chronic neuralgic pain as a consequence of nerve impairment in leprosy will be developed as soon as possible.


Assuntos
Uso de Medicamentos/estatística & dados numéricos , Uso de Medicamentos/tendências , Hospitais de Dermatologia Sanitária de Patologia Tropical/estatística & dados numéricos , Hanseníase/complicações , Hanseníase/tratamento farmacológico , Neuralgia/tratamento farmacológico , Neuralgia/etiologia , Prescrições/estatística & dados numéricos , Idoso , Analgésicos/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Doença Crônica , Feminino , Humanos , Japão/epidemiologia , Hansenostáticos/administração & dosagem , Masculino , Pentazocina/administração & dosagem , Fenilpropionatos/administração & dosagem , Tempo , Vitamina B 12/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...